GW Pharmaceuticals Plc (GWPH)

132.30
1.96 1.50
NASDAQ : Health Technology
Prev Close 130.34
Open 129.96
Day Low/High 128.25 / 132.88
52 Wk Low/High 105.12 / 179.65
Volume 407.94K
Avg Volume 560.00K
Exchange NASDAQ
Shares Outstanding 30.45M
Market Cap 3.97B
EPS -6.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Canopy Growth and 4 Other Cannabis Stocks That Look Good Here

Canopy Growth and 4 Other Cannabis Stocks That Look Good Here

These stocks offer some diversification or unique features in the legal-weed space.

Down the Marijuana Rabbit Hole: 5 Companies to Consider

It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy.  As you go down the marijuana rabbit hole, ...

Legalized Recreational Marijuana Won't Kill Medical Marijuana

Legalized Recreational Marijuana Won't Kill Medical Marijuana

Sales trends and the potential for stronger versions of prescription cannabis offer medical marijuana providers hope.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

Seven U.S. Stocks Offering Cannabis Exposure

Seven U.S. Stocks Offering Cannabis Exposure

While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.

Jim Cramer: These 4 Cold Stocks of Once-Hot Companies Could Reignite

Jim Cramer: These 4 Cold Stocks of Once-Hot Companies Could Reignite

It's important to know the difference between broken stocks and broken companies.

The Market Is Finally Rewarding Stock Picking

The Market Is Finally Rewarding Stock Picking

The game plan is to spot the charts that have more room to run.

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

Party leaders will have to work toward merging the two versions of tax reform into one final bill.

Enjoy the Holiday Trading While It Lasts

Enjoy the Holiday Trading While It Lasts

Market momentum goes on a rampage.

Fund Manager High On Marijuana, Zinc as Shelters in Pullback

Fund Manager High On Marijuana, Zinc as Shelters in Pullback

Growth is almost guaranteed in these two areas, says James McDonald of Index Strategy Advisors.

Rev's Forum: Stock Pickers Have Some Opportunities

Rev's Forum: Stock Pickers Have Some Opportunities

But the buyers are still unable to produce sustained momentum.

Cramer: How Do You Play This Answer to the Opiate Epidemic?

Cramer: How Do You Play This Answer to the Opiate Epidemic?

GW Pharma could be the answer to an opiate addiction that isn't understood.

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.

Jim Cramer Fields Questions From Viewers Including Henry Blodget

Jim Cramer Fields Questions From Viewers Including Henry Blodget

TheStreet's Jim Cramer tackled viewer questions on the economy from the NYSE Wednesday. His first viewer question was from Henry Blodget, an investor and CEO of Business Insider.

Cramer: Markets to Dip for a Few Weeks When the Fed Raises Rates

Cramer: Markets to Dip for a Few Weeks When the Fed Raises Rates

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

Here's What's Driving Biotech

And it's not the favorable macroeconomic climate.

That Was the Week That Was

That Was the Week That Was

Let's review.

Haze May Be Lifting for GW Pharma

This is one hot pot stock.

Nothing 'Healthy' About This Correction

All corrections are unhealthy when they involve earnings.

Remarkable Biotech Runs Continue

A Fed-related dip may be your only hope to get in lower.

What Is Wrong With You People?

These companies are doing great -- take some profits!

Where Did the Sellers Go?

But positives could be gone if oil dips to $43.

Off the Charts

Off the Charts

Baidu exploded to the upside today, while GW Pharmaceuticals broke down.

Can't Take the Heat? Get Out of Specs

Accept the risk you're taking on and, above all, be a grown-up about it.

A No-Drama Market

Not much reason to sell right now.

Why I'm Not High on GW Pharma

Forget marijuana, there's a more basic reason to be bearish.